• Publications
  • Influence
Pharmacokinetics of pyrazinamide and its metabolites in healthy subjects
The plasma and urine pharmacokinetic parameters of pyrazinamide and of its metabolites have been studied and the activity of a microsomal deamidase was found to be the limiting factor.
Interaction between allopurinol and pyrazinamide.
Analysis of the pharmacokinetic parameters showed that Al induced marked changes in levels of PZA metabolites and accumulation of pyrazinoic acid, which is directly responsible for the inhibition of renal urate secretion, so other drugs, which do not involve xanthine oxidase inhibition, should be used in the treatment of this side effect of chemotherapy.
Three-month follow-up of arterial blood gas determinations in candidates for long-term oxygen therapy. A multicentric study.
One hundred seventeen patients with severe chronic obstructive pulmonary disease whose PaO2 in a stable clinical state ranged from 41 to 59 mmHg, were included in a multicentric controlled study on
Haemodialysis of pyrazinamide in uraemic patients
The high dialysability shows that PZA can property be administered at the end of each dialysis session in the usual dose of 25 to 30 mg·kg−1.
Pharmacokinetics of pyrazinamide and its metabolites in patients with hepatic cirrhotic insufficiency.
The pharmacokinetics of pyrazinamide (Pirilène) and its metabolites are evaluated in ten subjects with hepatic insufficiency, after an oral dose of 19.3 +/- 0.6 mg.kg-1 and the results are compared